Medidata and SHYFT Analytics Form Commercial Partnership

Cloud Investing

Medidata (NASDAQ:MDSO) and SHYFT Analytics (SHYFT) announced a strategic commercial partnership to increase access to healthcare data analytics in clinical trials. As quoted in the press release: Using Medidata’s industry-leading clinical technology platform and SHYFT’s intelligent analytics, life sciences companies and their contract research organization (CRO) partners can analyze RWE data to improve study design …

Medidata (NASDAQ:MDSO) and SHYFT Analytics (SHYFT) announced a strategic commercial partnership to increase access to healthcare data analytics in clinical trials.
As quoted in the press release:

Using Medidata’s industry-leading clinical technology platform and SHYFT’s intelligent analytics, life sciences companies and their contract research organization (CRO) partners can analyze RWE data to improve study design and site selection, two of the most critical and costly components of successful drug development programs. The joint offering will provide insights that can be used to identify specific patient populations for studies across therapeutic areas, supporting efforts to design more effective protocols, more efficiently recruit study participants and uncover the best treatment paths in clinical practice.
“As life sciences companies embark on more complex and targeted programs in oncology, rare diseases and a range of therapeutic areas, embedding real world evidence data and outcomes-based analytics early in the clinical trial process is imperative for success,” said Mike Capone, Medidata’s chief operating officer. “Our partnership with SHYFT is part of our ongoing efforts to help life sciences companies realize the value of data assets, providing the capabilities to overcome key R&D challenges and, in doing so, speed time to market and more quickly deliver new medicines to patients.”

Click here for the full press release.

The Conversation (0)
×